Patents Examined by Sharmila Gollamudi
  • Patent number: 7973081
    Abstract: Composition containing quaternary ammonium compounds in which the nitrogen atom is substituted by at least one alkyl group having at least 12 carbon atoms, the composition including at least 20% in weight by weight of the total composition, of ammonium halides in which the nitrogen atom is substituted by at least one alkyl group having at least 14 carbon atoms and more than 5%, preferably more than 7% in weight by weight of the total composition, of ammonium halides in which the nitrogen atom is substituted by at least one alkyl group having at least 16 carbon atoms. Ophthalmic oil-in-water emulsions containing such compositions, the ophthalmic emulsions being useful for eye care or for the treatment of eye conditions are also disclosed.
    Type: Grant
    Filed: July 27, 2007
    Date of Patent: July 5, 2011
    Assignee: Novagali Pharma SA
    Inventors: Laura Rabinovich-Guilatti, Gregory Lambert, Frederic Lallemand, Betty Philips
  • Patent number: 7960366
    Abstract: Methods and compositions for treating for the synergistic treatment of fungal associated disorders are discussed.
    Type: Grant
    Filed: September 16, 2004
    Date of Patent: June 14, 2011
    Assignee: Paratek Pharmaceuticals, Inc.
    Inventors: Michael Draper, Mark L. Nelson
  • Patent number: 7939100
    Abstract: The present invention provides a tulobuterol adhesive patch comprising (a) a support, (b) an acrylic pressure-sensitive adhesive layer containing the percutaneously absorbing drug tulobuterol and if necessary a lipophilic oily plasticizer, and (c) a release liner, laminated in that order, wherein the acrylic pressure-sensitive adhesive is a copolymer obtained by copolymerizing an acrylic monomer which is acetoacetoxyalkyl (meth) acrylate with one or more other vinyl monomers, to yield a tulobuterol adhesive patch with excellent release and skin permeability of tulobuterol from the pressure-sensitive adhesive layer, low skin irritation and excellent safety.
    Type: Grant
    Filed: December 21, 2004
    Date of Patent: May 10, 2011
    Assignee: Saitama Daiichi Pharmaceutical Co., Ltd.
    Inventors: Naohisa Kawamura, Hidenori Sawada, Yoshiki Sugizaki, Takashi Saitoh
  • Patent number: 7935726
    Abstract: Provided are compounds of formula IA or IB: wherein R1 and R8 are independently optionally substituted hydrocarbyl groups; wherein (a) R1 contains a carbonyl group and a phenyl group, (b) R8 contains an optionally substituted adenine group, or (c) R8 contains an alkenyl group with from two to six carbon atoms; R10 is H, —OH, —OR or ?O; R6 is selected from the group consisting of: H, OH, alkyl, alkenyl, alkynyl, an aromatic ring system, amino, sulfhydryl, sulfonyl, NH2 and OCOR; R2 is selected from the group consisting of: H, —OH and lower alkyl; R is H or an optionally substituted hydrocarbyl group, and pharmaceutically acceptable salts or esters of the foregoing, as well as isomers thereof.
    Type: Grant
    Filed: April 29, 2004
    Date of Patent: May 3, 2011
    Assignee: Kansas State University Research Foundation
    Inventor: Duy H. Hua
  • Patent number: 7915307
    Abstract: Methods of improving the pharmacokinetics of doxepin in a patient.
    Type: Grant
    Filed: July 20, 2007
    Date of Patent: March 29, 2011
    Assignee: Somaxon Pharmaceuticals, Inc.
    Inventors: Cara Baron Casseday, Elizabeth Ludington, Michael Skinner, Susan Dubé, Roberta L. Rogowski, Philip Jochelson, Robert Mansbach
  • Patent number: 7915280
    Abstract: This invention relates to compounds, pharmaceutical compositions, and methods of using the disclosed compounds for inhibiting PARP.
    Type: Grant
    Filed: August 30, 2005
    Date of Patent: March 29, 2011
    Assignee: Eisai Inc.
    Inventors: Dana Victor Ferraris, Jia-He Li, Vincent Kalish, Jie Zhang
  • Patent number: 7910735
    Abstract: Substituted pyrazinecarboxylic acid anilide derivatives represented by the general formula (I) or salts thereof; intermediates of them; pesticides (such as insecticides and acaricides) for agricultural and horticultural use, containing the compounds as the active ingredient; and usage thereof: wherein R1 is H, C1-6 alkyl, halo C1-6 alkyl, or the like; R2 is halogeno, C1-6 alkyl, or the like; G is C2-10 alkyl or the like; Z is oxygen or sulfur; X's are each independently H, halogeno, or the like; Y's are each independently H, halogeno, cyano, or the like; and m and n are each an integer of 1 to 3.
    Type: Grant
    Filed: May 26, 2005
    Date of Patent: March 22, 2011
    Assignee: Nihon Nohyaku Co., Ltd.
    Inventors: Takashi Furuya, Kozo Machiya, Akiyuki Suwa, Shinsuke Fujioka
  • Patent number: 7893263
    Abstract: This invention relates to novel corosolic acid analogs of the formula I, wherein R1, R2, R3, R4 and R5 are described herein. These compounds exhibit good hypoglycemic and 5-lipoxygenase inhibitory activities. They also inhibit tumour growth. Pharmaceutical compositions containing known adjutants and the title compounds are also within the scope of this invention.
    Type: Grant
    Filed: July 8, 2004
    Date of Patent: February 22, 2011
    Assignee: Laila Nutraceuticals
    Inventors: Ganga Raju Gokaraju, Rama Raju Gokaraju, Venkata Subbaraju Gottumukkala, Trimurtulu Golakoti, Venkateswarlu Somepalli, Venkateswara Rao Chirravuri
  • Patent number: 7893302
    Abstract: The present invention relates to novel cationic lipids, transfection agents, microparticles, nanoparticles, and short interfering nucleic acid (siNA) molecules. The invention also features compositions, and methods of use for the study, diagnosis, and treatment of traits, diseases and conditions that respond to the modulation of gene expression and/or activity in a subject or organism. Specifically, the invention relates to novel cationic lipids, microparticles, nanoparticles and transfection agents that effectively transfect or deliver biologically active molecules.
    Type: Grant
    Filed: November 12, 2009
    Date of Patent: February 22, 2011
    Assignee: Sirna Therapeutics, Inc.
    Inventors: Tongqian Chen, Chandra Vargeese, Kurt Vagle, Weimin Wang, Ye Zhang
  • Patent number: 7887789
    Abstract: Polymeric reagents are provided comprising a moiety of atoms arranged in a specific order, wherein the moiety is positioned between a water-soluble polymer and a reactive group. The polymeric reagents are useful for, among other things, forming polymer-active agent conjugates. Related methods, compositions, preparations, and so forth are also provided.
    Type: Grant
    Filed: May 21, 2004
    Date of Patent: February 15, 2011
    Assignee: Nektar Therapeutics
    Inventors: J. Milton Harris, Antoni Kozlowski, Samuel P. McManus, Michael D. Bentley, Stephen A. Charles
  • Patent number: 7871632
    Abstract: The present invention provides compositions for delivering highly water-soluble drugs (such as vinca alkaloids) and methods of using such compositions.
    Type: Grant
    Filed: July 12, 2004
    Date of Patent: January 18, 2011
    Assignee: Adventrx Pharmaceuticals, Inc.
    Inventor: Andrew Xian Chen
  • Patent number: 7867289
    Abstract: A method of preparing a depilatory composition includes placing a quantity of sucrose into a heating vessel. Vinegar and citric acid are added into the heating vessel in the respective amounts of about 30 to 35% and 2.0 to 2.5% of the quantity of sucrose. The sucrose, vinegar and citric acid are stirred to create a mixture. The mixture is heated to about 230 degrees Fahrenheit. The mixture is diluted with water in an amount of 2.0 to 2.5% of the quantity of sucrose. The diluted mixture is cooled to form a soft was a room temperature once the temperature of the diluted mixture reaches about 230 degrees Fahrenheit.
    Type: Grant
    Filed: February 15, 2005
    Date of Patent: January 11, 2011
    Inventor: Madlen Postajian
  • Patent number: 7858599
    Abstract: An exemplary method of treating a urologic symptom includes administering a daily dose of creatine to an individual wherein the daily dose of creatine lies in a range from about 0.35 mg to about 3.5 mg per kilogram body weight. Such an exemplary method may further include administering a dose of a compound that inhibits phosphodiesterase (e.g., at a time less than approximately 4 hours prior to sexual activity). Other exemplary methods, compounds, compositions, etc., are also disclosed.
    Type: Grant
    Filed: December 28, 2006
    Date of Patent: December 28, 2010
    Inventor: Robert W. Hander
  • Patent number: 7851494
    Abstract: Compounds useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis, are disclosed.
    Type: Grant
    Filed: July 2, 2007
    Date of Patent: December 14, 2010
    Assignee: Wellstat Therapeutics Corporation
    Inventors: Shalini Sharma, Reid W. von Borstel, Kirvin L. Hodge, Michael K. Bamat, Stephen D. Wolpe
  • Patent number: 7837883
    Abstract: There are provided methods for controlling microbial or bioflim growth, comprising mixing a hypochlorite oxidant and at least one nitrogen-containing compound or salt thereof selected from a particular group of nitrogen-containing compounds and salts to form a biocide, and applying the biocide. Apparatus for practicing the methods are also provided.
    Type: Grant
    Filed: February 14, 2005
    Date of Patent: November 23, 2010
    Assignee: A. Y Laboratories Ltd.
    Inventor: Ayala Barak
  • Patent number: 7833540
    Abstract: The present invention provides a dermatological and/or cosmetic composition which includes a methoxycinnamate, and a cyclic nitroxide. The present invention further provides a method of synthesizing photo absorbing-antioxidant compounds and their use in dermatological and/or cosmetic compositions. In addition, the present invention relates to the use of methoxycinnamate, and nitroxide compounds for the preparation of a composition for the dermatological and/or cosmetic treatment of skin.
    Type: Grant
    Filed: December 15, 2006
    Date of Patent: November 16, 2010
    Assignee: Jarrow Formulas, Inc.
    Inventors: Elisabetta Damiani, Paola Astolfi, Lucedio Greci
  • Patent number: 7829573
    Abstract: The invention concerns the use of a combination of an anti-angiogenic agent and an anti-hypertensive agent for use in the manufacture of a medicament for the treatment of a disease state associated with angiogenesis in a warm-blooded mammal, such as a human being. The invention also relates to pharmaceutical compositions comprising an anti-angiogenic agent and an anti-hypertensive agent, to kits thereof and to a method of treatment of a disease state associated with angiogenesis which comprises the administration of an effective amount of a combination of an anti-angiogenic agent and an anti-hypertensive agent to a warm-blooded animal, such as a human being.
    Type: Grant
    Filed: April 2, 2001
    Date of Patent: November 9, 2010
    Assignee: AstraZeneca AB
    Inventors: Jon Owen Curwen, Donald James Ogilvie
  • Patent number: 7820732
    Abstract: Methods for modulating and enhancing thermal and mechanical properties and biocompatibilities of coatings on implantable devices are disclosed. Implantable devices containing the enhanced thermal and mechanical properties and biocompatibilities are also described. The implantable devices can be used to treat a medical condition such as vulnerable plaque or restenosis.
    Type: Grant
    Filed: April 30, 2004
    Date of Patent: October 26, 2010
    Assignee: Advanced Cardiovascular Systems, Inc.
    Inventors: Syed Faiyaz Ahmed Hossainy, Yiwen Tang, Harshad Borgaonkor, Jessica Reneé DesNoyer, Stephen D. Pacetti
  • Patent number: 7820700
    Abstract: The present invention relates to a novel 2-phenylpyridine derivative or a salt thereof, wherein the pyridine ring is substituted with a carboxyl group or the like and the benzene ring has an electron-withdrawing group such as a cyano group and an electron-donating group such as a substituted alkoxy group at the same time. Since the compound of the invention has good xanthine oxidase-inhibitory action and uric acid-lowering action and does not have a structure derived from nucleic acid, the compound has advantages of high safety and excellent effects as compared with conventional compounds and is useful as a therapeutic or preventive agent for hyperuricemia, gout, inflammatory bowel diseases, diabetic kidney diseases, diabetic retinopathy, or the like.
    Type: Grant
    Filed: August 26, 2005
    Date of Patent: October 26, 2010
    Assignee: Astellas Pharma Inc.
    Inventors: Junji Miyata, Ryo Naito, Masakatsu Kawakami, Toru Asano
  • Patent number: 7816397
    Abstract: The invention relates to compounds of general formula (1): in which R1, R2, R3, R4, R5, A, B, D and E are as defined in Claim 1, and also to the preparation process therefor and the therapeutic use thereof. These compounds can be used in the treatment of pathologies associated with hyperglycaemia.
    Type: Grant
    Filed: June 1, 2005
    Date of Patent: October 19, 2010
    Assignee: Merck Patent GmbH
    Inventors: Gérard Moinet, Gérard Botton, Micheline Kergoat